SPSai Parenterals544742Quarterly results

Q2 FY27 results, buyout of remaining 25% in SP Analytics, Saicriti Pharma deal completed

Board meeting held on 01 November 2026 approved un-audited standalone and consolidated results for the quarter and half year ended 30 September 2026; the statutory auditors issued an unmodified conclusion on the limited review.

By ScoutQuest · Sun 1 Nov 2026, 2:52 PM IST · 3 min read

Consolidated revenue from operations (Q2)

₹ 1,949.18 million for the quarter ended 30 September 2026 (₹ 535.28 million in the same quarter last year)

Consolidated profit after tax (Q2)

₹ 105.10 million (₹ 63.50 million)

Consolidated EPS (basic and diluted, Q2)

₹ 2.38 for the quarter and ₹ 4.17 for the half year

The board met on Sunday, 01 November 2026 at 12:30 p.m. and the meeting concluded at 2:30 p.m. Along with the accounts, the board cleared a stake purchase and a committee formation, and the company also confirmed completion of an earlier approved acquisition.

The numbers (un-audited, consolidated)

• Revenue from operations for the quarter ended 30 September 2026 was ₹ 1,949.18 million, against ₹ 535.28 million in the quarter ended 30 September 2025.
• Profit after tax for the quarter was ₹ 105.10 million, against ₹ 63.50 million a year earlier.
• For the half year, revenue from operations was ₹ 3,735.90 million and profit after tax ₹ 184.33 million, against ₹ 869.18 million and ₹ 77.64 million respectively in the half year ended 30 September 2025.
• All figures are as printed in ₹ millions. The statutory auditors carried out a Limited Review and issued an unmodified conclusion. The company reported no exceptional and/or extraordinary items for the quarter ended 30 September 2026.
• On a standalone basis, revenue from operations was ₹ 529.09 million and profit after tax ₹ 64.86 million for the quarter; for the half year, ₹ 1,056.87 million and ₹ 153.61 million.
• Earnings per share (basic and diluted, after exceptional items), consolidated, was ₹ 2.38 for the quarter and ₹ 4.17 for the half year; standalone it was ₹ 1.47 and ₹ 3.48.

Buying out the minority in SP Analytics

• The board approved acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private Limited, a subsidiary in which the company holds 75%, thereby making it a wholly owned subsidiary.
• Consideration is cash: 2,500 equity shares of face value Rs.10/- each, aggregating to Rs.25,000/-.
• SP Analytics was incorporated on November 16, 2023 to undertake testing, analysis and examination of pharmaceuticals, medicines, drugs and other related materials. The company has reported nil turnover during the last three financial years.
• The acquisition falls within the ambit of Related Party Transactions; the promoter/promoter group has an interest in the entity by virtue of their relationship with it. The transaction is proposed to be undertaken at arm's length, based on terms mutually agreed and supported by an appropriate assessment, wherever applicable.
• Indicative time period for completion of the acquisition: on or before 31.12.2026.

Saicriti Pharma: 60% acquisition completed

• Pursuant to the board approval at its meeting held on August 11, 2026, the company has completed the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited.
• Consequent to this, Saicriti Pharma Private Limited has become a subsidiary of the company with effect from the date of completion of the acquisition.

New Management Committee

• A five-member committee was constituted "for smooth functioning and administration convenience of the Company":
• Anil Kumar Karusala, Managing Director — Chairman
• Vijitha Gorrepatti, Whole Time Director — Member
• Kunal Kakumanu, Executive Director — Member
• Arvind Gannimitta, Chief Operating Officer — Member
• Ashwani Singh Bisht, Company Secretary & Compliance Officer — Member

What a reader can take away

• The two shareholding actions point in the same direction: SP Analytics moves from 75% to 100% ownership for a cash outlay of Rs.25,000/-, and Saicriti Pharma has already become a subsidiary at 60%.
• SP Analytics is an early-stage entity by the update's own description — incorporated in November 2023, with nil turnover reported over the last three financial years.
• The results carry an unmodified review conclusion, and the board also took note of the Limited Review Reports for both standalone and consolidated accounts.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev